Neflamapimod, an experimental oral therapy from Cervomed, has been selected for inclusion in the U.K.-funded EXPERTS-ALS platform study.

NeuroSense is engaging with regulatory authorities to advance PrimeC into pivotal trials.

Add Yahoo as a preferred source to see more of our stories on Google. Neurizon hopes to initiate its regimen of the HEALEY-ALS trial in Q4 2025. Image credit: MAXIMUM ART / Shutterstock.com (MAXIMUM ...

A new treatment for amyotrophic lateral sclerosis, or ALS, has been approved by the US Food and Drug Administration. The FDA announced approval of Relyvrio, developed by Amylyx Pharmaceuticals, on ...

AB Science says a newly identified blood biomarker may help assess masitinib activity in its ongoing Phase 3 ALS clinical trial.

Eight years after receiving a life-shattering diagnosis, a New Jersey mother credits an “amazing” new drug for stopping her disease in its tracks. Raziel Green, 52, an active runner and mother of two, ...

Scientists have learned more about the effects of an experimental amyotrophic lateral sclerosis (ALS) drug candidate that failed its promise. This study has shown that the drug was able to enter the ...

Dr. Rakesh Parekh was in his mid-40s when he first noticed something was wrong: During his workouts, his left arm was weaker and struggled to keep up. Initially, Parekh, an emergency medicine doctor ...

The amyotrophic lateral sclerosis market is expected to grow owing to the increasing prevalence of the disease, along with the promising emerging pipeline therapies, such as Masitinib (AB Sciences), ...

Rickey Malloy (left), who receives tofersen treatment for SOD1-ALS at WashU Medicine, plays a round of golf with his wife, Jenny, and their son, Kash. Long-term use of tofersen, a new drug approved by ...

Neurizon hopes to initiate its regimen of the HEALEY-ALS trial in Q4 2025. Image credit: MAXIMUM ART / Shutterstock.com The US Food and Drug Administration (FDA) has released its clinical hold on ...